<html><body>
<h2>Case: Test Case: DM and no drugs</h2>
62.0 year old 
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">62</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Creatinine</td><td width="200">2.0</td><td width="200">2008-7-15</td></tr>
<tr><td width="200">HbA1C</td><td width="200">9</td><td width="200">2008-7-11</td></tr>
<tr><td width="200">BMI</td><td width="200">28</td><td width="200">2008-7-11</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">8.0</td><td width="200">2008-6-1</td></tr>
</table>
<p><b>Medications:</b> 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Data Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200">SSN</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-02-21</td>
<td width="200">Diabetes_Mellitus</td></tr>
<tr> <td width="200"></td>
<td width="200">2008-07-15</td>
<td width="200">Sex</td></tr>
</table><p>
<h2 align="center">ATHENA Cardiovascular Guidelines</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Cardiovascular Guidelines: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>()</i>]
</ul>
<h2 align="center">ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(62.0/1970-1-1) && null)</i>]
</ul>
<b>Scenario choice:</b> DM and no Cr & urine assessment within a year, no CKD
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
<li><b>Order Cr & microalbumin/Cr ratio <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of Cr AND microalbumin/creatinine within a year</i> evaluate to <b> true</b> because <i>null</i>)])
Absence of serum creatinine and microalbumin/creatinine ratio within a year; please order both now.
</ul>
</ul>
<h2 align="center">ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
<li><b>Refer for eye exam within 3m <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM type 2 newly diagnosed or insulin or ocular risk or diabetes type 1 >= 3 years</i> evaluate to <b> true</b> because <i>null</i>)])
Referral should be scheduled for 3 months from today (max)
</ul>
</ul>
<h2 align="center">ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> Not wound-followup DM patients
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Initial assessments</b><br>
<ul>
<li><b>Perform and document foot risk assessment (B) and visual inspection of feet <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

Perform and document visual inspection of patient's feet.
<li><b>Assess if limb threatening condition present <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])

</ul>
<li><b>Evaluate </b><br>
<ul>
</ul>
</ul>
<h2 align="center">ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null)</i>]
<li>Overweight (25<BMI<29): [because <i> 25<BMI<29 </i> evaluate to <b>true</b><i>(BMI(28.0/2008-7-11) && BMI(28.0/2008-7-11))</i>]
<li>Creatinine > 1.5 and Male: [because <i> Creatinine > 1.5 and Male </i> evaluate to <b>true</b><i>(Creatinine(2.0/2008-7-15) && Sex(Male compared to Male))</i>]
</ul>
<b>Scenario choice:</b> Nonpharmacologic Therapy
<p>
<b>Goal:</b> HBA1C <= target(presence of target HBA1C)
<p><b>Reached goal?</b> failed(HbA1C(9.0/2008-7-11; target:8.0))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li>Consider aspirin therapy to reduce the risk of cardiovascular fatal events.()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Nonpharmacologic therapy</b><br>
<ul>
<li><b>Start aspirin <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Consider aspirin therapy to reduce the risk of cardiovascular fatal events.
</ul>
<li><b>DM - No meds</b><br>
<ul>
<li><b>Is patient high risk? If yes, refer <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

null
<li><b>Metformin contraindicated, add Glipizide <font color=FF0000>preferred</font></b>(strict rule-in condition<i> HbA1C > Target_HbA1c</i> evaluate to <b> true</b> because <i>HbA1C(9.0/2008-7-11; target:8.0)</i>)])
Add Glipizide
</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>GLIPIZIDE
<ul>
<li>•	Efficacy ( HbA1c) a = 1.0 - 2.0 %
•	1st generation sulfonylureas are no longer commonly used.
•	No difference in long term efficacy or failure rate has been demonstrated among the sulfonylureas.
•	The preferred agents have shorter half-lives and inactive metabolites.
•	1st generation sulfonylureas are 100% renally eliminated. Chlorpropamide and tolazamide have active metabolites.
•	Glipizide, glyburide, and glimepiride are renally eliminated by 80 - 85%, 50%, and 60% respectively. All but glipizide have active metabolites.
•	Inexpensive
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && Age(62.0/1970-1-1))</i>]
<li>CHD or CHD-Equivalent: [because <i> CHD Risk Equivalent </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> No drug, high CHD risk
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Primary_Recommendation</b>
<ul>
<li><b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>()
<li><b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Management Choice</b><br>
<ul>
<li><b>Order lipid study <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Absence of LDL data in last year</i> evaluate to <b> true</i>)])
null
<li><b>TLC initiation <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Criteria for initiation for TLC</i> evaluate to <b> true</b> because <i>null</i>)])
<b><font color=red>Start Therapeutic lifestyle changes to achieve LDL goal.  Check lipid profile in 3 months.</font>
<li><b>Presence of CHD, Initiate statin therapy <font color=FF0000>preferred</font></b>(strict rule-in condition<i> Presence of CHD or CHD Equivalent</i> evaluate to <b> true</i>)])
<b><font color=red>Initiate statin therapy and therapeutic lifestyle changes</font>

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Statin Metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
<li>Statin Not metabolized by CYP3A4
<ul>
<li><font color=FF0000>Compelling indications:  CHD_Or_CHDEquivalent(CHD or CHD-Equivalent[null]) </font>
<li>Liver function test recommended before initiating statin therapy and clinically indicated thereafter.  Possible Adverse reaction is increase in LFTs >3x upper limit and CPKs > 10x upper limit
<li>preference: preferred
</ul>
</ul>
<h2 align="center">ATHENA Heart Failure Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)null)</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> unknown(Treatment_Diastolic_BP(no value) && Treatment_Systolic_BP(no value))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> unknown(LDL_Cholesterol(no value))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)()
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)()
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)()
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)()
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>null</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>Refer to specific ACE Inhibitor dose adjustments based on kidney function.
<li>Need to find content
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[null]) 
<li>preference: preferred
</ul>
</ul>
<h2 align="center">VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that null)</i>]
</ul>
No scenario chosen.
</body></html>
